Breath analysis to detect fungal infections in leukemia patients
Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients
This study is testing if analyzing breath samples can help doctors detect fungal infections in leukemia patients who are at high risk due to their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Zurich Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Zurich, Canton of Zurich) |
| Trial ID | NCT06537726 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with leukemia who are at high risk for invasive fungal infections (IFI) due to chemotherapy-induced neutropenia. It aims to identify specific volatile biomarkers associated with IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS). The approach is non-invasive, which is crucial for patients who cannot undergo traditional diagnostic procedures due to severe thrombocytopenia. By analyzing breath samples, the study seeks to improve the accuracy of IFI diagnosis in this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with acute leukemia who are undergoing chemotherapy and have neutropenia.
Not a fit: Patients who are unable to follow instructions for breath analysis or have anatomical abnormalities preventing the use of a mouthpiece will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a non-invasive method for early detection of invasive fungal infections in leukemia patients, potentially reducing morbidity and mortality.
How similar studies have performed: While the use of breath analysis for diagnostic purposes is an emerging field, this specific approach using SESI-HRMS for detecting fungal infections in leukemia patients is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of acute leukemia * Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer * Neutropenia (\<500/µl) present at inclusion or planned chemotherapy with expected neutropenia (\<500/µl) for more than 7 days Exclusion Criteria: * Unable to follow instructions for breath analysis * Anatomic abnormalities precluding the use of a mouthpiece for breath analysis
Where this trial is running
Zurich, Canton of Zurich
- University Hospital of Zurich — Zurich, Canton of Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Jeremy Deuel, PD Dr. — University of Zurich
- Study coordinator: Jeremy Deuel, PD Dr.
- Email: jeremy.deuel@usz.ch
- Phone: +41 44 255 11 11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.